



NMS Labs

CONFIDENTIAL

200 Welsh Road, Horsham, PA 19044-2208
Phone: (215) 657-4900 Fax: (215) 657-2972
e-mail: nms@nmslabs.com

Robert A. Middleberg, PhD, F-ABFT, DABCC-TC, Laboratory Director

Demo Report

Report Issued 03/30/2020 11:07
Last Report Issued 11/14/2011 06:09

88888
Clinical Example Report
Attn: Example Reports
200 Welsh Road
Horsham, PA 19044

Patient Name 0013SP-POS
Patient ID 0013SP-POS
Chain 11003489
Age Not Given DOB Not Given
Gender Not Given
Workorder 11003489
Received 11/14/2011 06:06

Sample ID 11003489-001
Matrix Serum or Plasma
Patient Name 0013SP-POS
Patient ID 0013SP-POS
Container Type Clear vial

Collect Dt/Tm Not Given
Source Not Given

Approx Vol/Weight Not Given

Receipt Notes None Entered

Table with 5 columns: Analysis and Comments, Result, Units, Reporting Limit, Notes

0013SP Acamprosate, Serum/Plasma

Analysis by High Performance Liquid Chromatography/
Tandem Mass Spectrometry (LC-MS/MS)

Table row for Acamprosate: Result 100, Units ng/mL, Reporting Limit 50

Synonym(s): Campral; N-acetylhomotaurine; calcium acetylhomotaurinate

Acamprosate is a synthetic psychotropic drug used in
the treatment of alcohol dependence. It has been shown
to reduce cumulative days drinking and alcohol-induced
cravings. Upon ingestion, acamprosate immediately
dissociates into N-acetyl homotaurine; this is the
compound that is measured and reported.
Steady-state acamprosate concentrations following
2 x 333 mg tablets three times daily ranged from
370 +/- 145 to 644 +/- 386 ng/mL and were achieved
3.5 +/- 0.5 to 9.0 +/- 1.9 hours after dose.

This test was developed and its performance characteristics determined by NMS Labs. It has not been cleared or approved by the US
Food and Drug Administration.